Get started
Author

Gaia Giannone

Observed names: G Giannone, G. Giannone
Observed institutions: Imperial College Healthcare NHS Trust, Hammersmith Hospital, Ovarian Cancer Action, Candiolo Cancer Institute, Imperial College London, University of Turin
ORCID: 0000-0003-1991-039X
Observed ORCID: 0000-0003-1991-039X
OpenAlex ID: A5080241438
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
2020 · Gaia Giannone, Eleonora Ghisoni, et al. · International Journal of Molecular Sciences · 163
PDF
PARP Inhibitors in Ovarian Cancer
2018 · Gloria Mittica, Eleonora Ghisoni, et al. · Recent Patents on Anti-Cancer Drug Discovery · 159
PDF
Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
2017 · Gloria Mittica, Eleonora Ghisoni, et al. · Oncotarget · 115
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome
2019 · Sabrina Chiara Cecere, Gaia Giannone, et al. · Gynecologic Oncology · 108
PDF
Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications
2019 · Gaia Giannone, Laura Attademo, et al. · Cancers · 103
PDF
Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
2020 · Fulvio Borella, Eleonora Ghisoni, et al. · Diagnostics · 95
PDF
The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma
2023 · Philip Smith, Thomas Bradley, et al. · Nature Communications · 64
PDF
HPV vaccination and HPV-related malignancies: impact, strategies and optimizations toward global immunization coverage
2022 · Gaia Giannone, Anna R. Giuliano, et al. · Cancer Treatment Reviews · 63
The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
2022 · Z. Cheng, H. Mirza, et al. · Clinical Cancer Research · 54
PDF
A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience
2018 · Eleonora Ghisoni, Dionyssios Katsaros, et al. · Journal of Ovarian Research · 36
PDF
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study
2021 · Gennaro Daniele, Francesco Raspagliesi, et al. · International Journal of Gynecological Cancer · 35
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
2019 · Gaia Giannone, Valentina Tuninetti, et al. · International Journal of Molecular Sciences · 34
PDF
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
2019 · Eleonora Ghisoni, Furio Maggiorotto, et al. · Journal of Ovarian Research · 32
PDF
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial
2023 · Susana Banerjee, Gaia Giannone, et al. · JAMA Oncology · 30
PDF
Artificial Intelligence in Gynecological Oncology from Diagnosis to Surgery
2025 · Stefano Restaino, Maria Rita De Giorgio, et al. · Cancers · 27
PDF
The genomic trajectory of ovarian high‐grade serous carcinoma can be observed in STIC lesions
2024 · Zhao Cheng, Darren P Ennis, et al. · The Journal of Pathology · 25
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors
2021 · M. Bartoletti, L. Musacchio, et al. · Cancer Treatment Reviews · 25
Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series
2018 · G. Giannone, A. Milani, et al. · The Breast · 20
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
2021 · Margherita Turinetto, Giulia Scotto, et al. · Frontiers in Oncology · 19
PDF
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21)
2021 · Grazia Artioli, Gaia Giannone, et al. · Gynecologic Oncology · 18
PDF
Veliparib: A New Therapeutic Option In Ovarian Cancer?
2019 · Eleonora Ghisoni, Gaia Giannone, et al. · Future Oncology · 16
A tumour-derived organoid biobank maps cancer gene dependencies
2026 · C. Herranz-Ors, S. G. Bhosle, et al. · Nature · 14
Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience
2020 · Valentina Tuninetti, Marilena Di Napoli, et al. · Cancers · 14
PDF
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group
2022 · Michele Bartoletti, Alice Bergamini, et al. · International Journal of Gynecological Cancer · 13
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis
2022 · Lucia Musacchio, Anna Amela Valsecchi, et al. · Cancer Treatment Reviews · 11
Works count: 98
Citation count: 1,381
H-index: 19
I10-index: 27
Year
Topic
Type